| Species |
Human |
| Protein Construction |
IgG1 Fc (Asp104-Lys330)
Accession # P01857-1 |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Human FcRn, His Tag captured on CM5 Chip via antihis antibody can bind IgG1 Fc, Human in SPR assay (Biacore T200). Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
25.5 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 31-33 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IgG1 is most abundant in serum among the four IgG subclasses (IgG1, 2, 3 and 4) and binds to Fc receptors (FcγR) on phagocytic cells with high affinity. Fc fragment is demonstrated to mediate phagocytosis, trigger inflammation, and target Ig to particular tissues.IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases. |
| Synonyms |
IgG1; Igh-4; RGD1359539; VH7183 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
